New osteoporosis treatment breakthrough targets dormant bone cells

Researchers at Seoul National University have uncovered a new molecular pathway that could improve osteoporosis treatment. Their findings suggest that targeting two key regulators—TGF-β and sclerostin—may restore bone density more effectively than current methods.

The study focused on reactivating dormant bone cells to combat the loss of bone mass, a hallmark of osteoporosis. Osteoporosis weakens bones by reducing their mass and disrupting their structure, increasing fracture risks. The team examined osteoblasts, the cells responsible for bone formation, which exist in three states: active, inactive (quiescent), and reactivated after treatment.

Using advanced transcriptomic techniques, they mapped how the TGF-β signalling pathway controls osteoblast dormancy. Blocking TGF-β alone helped wake these inactive cells, boosting bone formation. But when combined with anti-sclerostin therapy—a treatment that targets a protein inhibiting bone growth—the effect was even stronger.

In tests on mice with hindlimb unloading (a model mimicking bone loss), the dual approach significantly improved bone volume and density. The combination also increased the number and thickness of osteoblast lineage cells, suggesting a broader recalibration of skeletal health.

The study highlights sclerostin as a key target for reviving dormant bone-lining cells, while TGF-β inhibition enhances this reactivation process. These results point to a potential breakthrough in osteoporosis care. By simultaneously blocking TGF-β and sclerostin, researchers achieved greater bone recovery than with existing treatments. The approach could lead to therapies that more effectively restore skeletal strength in patients.